Wafra Inc. Sells 61,174 Shares of Danaher Co. (NYSE:DHR)

Wafra Inc. cut its position in Danaher Co. (NYSE:DHRFree Report) by 37.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 102,941 shares of the conglomerate’s stock after selling 61,174 shares during the quarter. Danaher makes up approximately 1.4% of Wafra Inc.’s investment portfolio, making the stock its 22nd largest holding. Wafra Inc.’s holdings in Danaher were worth $23,814,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Banco Santander S.A. bought a new stake in Danaher during the 3rd quarter valued at approximately $683,000. Cary Street Partners Investment Advisory LLC grew its stake in shares of Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after acquiring an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. increased its position in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares during the period. Cercano Management LLC raised its stake in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Danaher stock traded up $0.96 during trading hours on Friday, hitting $265.80. 3,187,418 shares of the stock were exchanged, compared to its average volume of 2,621,433. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $265.94. The business’s 50-day moving average is $248.74 and its two-hundred day moving average is $236.19. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock has a market capitalization of $196.88 billion, a P/E ratio of 45.05, a P/E/G ratio of 4.08 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.36 EPS. Equities research analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 172,540 shares of company stock worth $43,523,481. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on DHR shares. Citigroup upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. TD Cowen lifted their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Raymond James lifted their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Bank of America increased their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $267.31.

Read Our Latest Analysis on Danaher

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.